About Glufosfamide: Glufosfamide is a third-generation alkylating agent designed for greater specificity and tumor uptake, with reduced systemic toxicities and side effects. It has been evaluated in more than 450 patients, with promising activity in several cancer types. Eleison has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 international randomized trial. This pivotal trial, which is expected to commence 2H-2011, will enroll patients with relapsed or refractory pancreatic cancer following prior chemotherapy treatment. It is designed to evaluate the efficacy of Eleison drug candidate glufosfamide in a controlled study in the second-line treatment of pancreatic cancer. About
Eleison Pharmaceuticals to License South Korean Marketing Rights of Glufosfamide for the Treatment of Pancreatic Cancer to Daewoong Pharmaceuticals Co., Ltd. Princeton, NJ, October 26, 2011 -- Eleison Pharmaceuticals, Inc., a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, has announced it has licensed to Daewoong Pharmaceuticals the marketing rights of the pancreatic drug candidate glufosfamide in the Republic of Korea. Mr. Edwin Thomas, CEO of Eleison Pharmaceuticals commented, “We are highly pleased to have as a partner Daewoong Pharmaceuticals, a leader and top-tier pharmaceutical company in South Korea and ideally capable of bringing glufosfamide to the Korean market.” Dr. Jong Wook Lee, President and CEO of Daewoong Pharmaceutical Co. Ltd. commented, “Glufosfamide has the potential to be an important new treatment for a difficult disease with few therapeutic options. We are pleased and dedicated to its successful development in Korea as the therapy reflects Daewoong's long-term commitment to provide safer, more effective treatment options to oncology patients." Under the terms of the license agreement, Daewoong Pharmaceuticals will be responsible for obtaining regulatory approvals, marketing, and distribution of glufosfamide in the Korean market. Eleison has received an up-front license fee and is entitled to receive future milestone payments and royalties. About Glufosfamide Glufosfamide is a third-generation alkylating agent designed for greater specificity and tumor uptake, with reduced systemic toxicities and side effects. It has been evaluated in more than 450 patients, with promising activity in several cancer types. Eleison has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for a Phase 3 international randomized trial. This pivotal trial, which is expected to commence 1H-2012, will enroll patients with relapsed or refractory pancreatic cancer following prior chemotherapy treatment. It is designed to evaluate the efficacy of Eleison drug candidate glufosfamide in a controlled study in the second-line treatment of pancreatic cancer. About Pancreatic Cancer Although pancreatic cancer is among the rarer cancer types, it is the fourth leading cause of death by cancer in the United States. More than 40,000 Americans are diagnosed with pancreatic cancer annually, resulting in approximately 38,000 deaths each year. There exist few therapeutic options to treat the disease and no drugs approved for second-line use. Five year survival rates are typically less than 5%. About Eleison Pharmaceuticals Eleison’s mission is to acquire, develop, and commercialize clinical stage drug candidates for "orphan" oncology indications, providing new hope for patients with rare life-threatening diseases. The Company has two programs in late-stage development and is in discussions to acquire other promising candidates for rare cancers. Eleison was founded in 2009 and is headquartered in Princeton, NJ. About Daewoong Daewoong Pharmaceutical Co. Ltd. is a leading Korean pharmaceutical company with annual turnover of nearly $680 million U.S. in 2010. Daewoong Pharmaceutical Co. Ltd. was ranked in the first position in South Korean pharmaceutical market in terms of requested reimbursement totals, according to Health Insurance Review Agency (HIRA). Daewoong has expanded global business operations throughout Asia and is currently developing strategies for the global market.
77 ：
Daewoong Pharmaceutical Co. Ltd. engages in the research, development, manufacturing and marketing of healthcare products. It provides a full spectrum of healthcare products for various therapeutic areas that include infectious diseases, cardiovascular diseases, metabolic disorders, disorder of central nervous system, digestive disorders, oncology and vaccines. Daewoong's R&D activity explores a broad spectrum of innovative approaches and has developed new products in key therapeutic area such as EGF for mucositis and wound healings and DWP05195 for Neuropathic Pain. In particular, Daewoong Pharmaceutical Co. Ltd. has made numerous successful partnerships with multinational pharmaceutical companies launching number of blockbuster products on the Korean market, and its strong growth is attributable to its dedication to excellence in sales and marketing, which is backed by a comprehensive portfolio of both innovative and generic prescription drugs. http://daewoong.com/ Page 2 of 2 Page 2 Forward Looking Statements Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Eleison’s product candidates, their uses and potential benefits and clinical trial results and plans. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Eleison’s ability to enroll and complete its current and anticipated clinical trials, the time and expense required to conduct such clinical trials and yze data, the possibility that results from these trials will not be confirmed, potential adverse side effects, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Eleison does not intend to update any forward-looking statement made in this news release. SOURCE: Eleison Pharmaceuticals, Inc. CONTACT: Eleison Pharmaceuticals, Inc. Corporate Communications 103 Carnegie Center, Suite 300 Princeton, NJ 08540 215-554-3530 info@eleison-pharma.com だそうです(・∀・)！
